Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLA: MB02 vs Avastin in NSCLC
NCT03296163Phase 3Completed
- Sponsor
- mAbxience
- Start
- Feb 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of bevacizumab MB02 in non-small cell lung cancer (NSCLC), sponsored by mAbxience. Started Feb 2018; status: completed.
02
Drugs
bevacizumab MB02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03296163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296163.